Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
UNC Lineberger Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
University Hospital, Brest
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
Royal Marsden NHS Foundation Trust
VLP Therapeutics
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
Maastricht University Medical Center
Centre Henri Becquerel
Institut de Cancérologie de Lorraine
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Alpha Tau Medical LTD.
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts Eye and Ear Infirmary
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
University of Chicago
New York University
Radboud University Medical Center
TScan Therapeutics, Inc.
University of Kentucky
University of Arkansas
Sanford Health
Insel Gruppe AG, University Hospital Bern
Vanderbilt-Ingram Cancer Center
Samsung Medical Center
Geisinger Clinic
3B Pharmaceuticals GmbH
Al-Azhar University
Bicara Therapeutics
QBiotics Group Limited
Providence Health & Services